Preclinical Pipeline Articles & Analysis
8 news found
Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. ...
At the NK2022 conference, the Company presented preclinical data demonstrating that AFM28 exhibits greater cell surface retention on NK cells than conventional monoclonal antibodies. Furthermore, AFM28 induced lysis of CD123-positive tumor cells when pre-complexed or when co-administered with cryopreserved NK cells, suggesting that AFM28 in combination with NK cells maintains ...
The financing will be used to advance the Company’s preclinical pipeline of therapeutics and the Company’s discovery partnerships. ...
I share the team’s vision of industrializing drug discovery with technology, and I’m excited to accelerate the advancement of our wholly-owned small molecule pipeline through preclinical development and into the clinic.” Dr. ...
” Deep Genomics has validated the proficiency of its AI Workbench by advancing a lead cohort of ten programs into preclinical research and expects to nominate twenty more in the next three years. “By applying its innovative AI platform to create oligonucleotides as ‘programmable medicines,’ Deep Genomics has demonstrated remarkable productivity in ...
“This financing further validates the significant advances in our AI discovery platform and growth of our proprietary preclinical pipeline,” said Brendan Frey, PhD, FRSC, Founder & CEO of Deep Genomics. ...
This financing will enable us to expand our AI technology in the pursuit of new therapeutic opportunities, to advance our Wilson program into the clinic, and to strategically partner assets emerging from our overflowing preclinical pipeline.” Deep Genomics uses AI to power every stage of drug development, from identifying therapeutic targets that were ...
Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel (immuno-modulatory progenitor [iMP] cells) to Daiichi Sankyo. Daiichi Sankyo will undertake all development, regulatory and commercial activities for iMP cells in the territory of Japan only, while CTL retains its worldwide rights outside of Japan as well as global ...